Mia Erbeznik, NP
Nurse Practitioner · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Mia Erbeznik’s office at (415) 600-1020 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
Original Medicare doctor bills
$26,581
Medicare paid this office $26,581 for 267 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| New patient visit (30+ min) | 111 | $8,355 | $75 |
| Return visit (30+ min) | 55 | $5,804 | $104 |
| New patient visit (45+ min) | 44 | $4,902 | $111 |
| Short return visit (20+ min) | 44 | $3,698 | $71 |
| Long return visit (40+ min) | 20 | $2,628 | $125 |
See all 6 services
| New patient visit (30+ min) | 111 | $8,355 | $75 |
| Return visit (30+ min) | 55 | $5,804 | $104 |
| New patient visit (45+ min) | 44 | $4,902 | $111 |
| Short return visit (20+ min) | 44 | $3,698 | $71 |
| Long return visit (40+ min) | 20 | $2,628 | $125 |
| New patient visit (15+ min) | 15 | $830 | $55 |
Who their Medicare patients are
267 Original Medicare patients in 2024. Average age 79 · Women 57% · Health risk score 0.89. At or below the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 59% · Coronary heart disease 22% · Chronic kidney disease 21% · Atrial fibrillation 20% · Diabetes 18% · Cancer 16% · Depression 10% · COPD 8% · Heart failure 7% · Stroke 7%.
The office billed $118,179, Medicare allowed $37,835 and paid $26,581; for 304 services of 8 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 267 | 304 | 79 | 0.89 | $118,179 | $26,581 |
| 2023 | 98 | 116 | 78 | 0.91 | $53,870 | $14,172 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| New patient visit (45+ min) | 31 | $4,013 | $129 |
| Long return visit (40+ min) | 25 | $3,620 | $145 |
| Return visit (30+ min) | 25 | $2,703 | $104 |
| New patient visit (60+ min) | 11 | $1,935 | $176 |
| New patient visit (30+ min) | 13 | $1,182 | $91 |
Drugs they prescribed that Part D paid
$22,965
Pharmacies billed $22,965 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 190) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
139 generic and 51 brand-name prescriptions · $22,965 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Linzess | 11 | $7,946 | $722 |
| Sod Sulf-Potass Sulf-Mag Sulf | 52 | $3,396 | $65 |
| Famotidine | 37 | $552 | $15 |
| Omeprazole | 25 | $367 | $15 |
| Peg 3350-Electrolyte | 19 | $352 | $19 |
Year by year
| 2024 | 190 | 116 | 0% (0) | 27% | $22,965 |
| 2023 | 54 | 46 | 0% (0) | 43% | $6,112 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Sod Sulf-Potass Sulf-Mag Sulf | 30 | $2,262 | $75 |
Money from drug and device companies
$1,512 in 2025
| 2025 | 5 | 33 | None | $1,512 |
| 2024 | 1 | 1 | None | $14 |
| 2023 | 4 | 8 | None | $579 |
| 2022 | 2 | 2 | None | $233 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Creon | $767 | 17 payments
|
| Lilly USA | Omvoh | $276 | 7 payments
|
| Janssen Biotech | Tremfya | $197 | 7 payments
|
| Phathom Pharmaceuticals | Voquezna | $149 | 1 payment
|
| Genzyme | Dupixent | $123 | 1 payment
|
See all 33 published payments
| Lilly USA | Meals · 2025-10-22 | Omvoh | $24 |
| Abbvie | Meals · 2025-10-18 | Rinvoq | $27 |
| Abbvie | Meals · 2025-09-29 | Rinvoq | $27 |
| Abbvie | Meals · 2025-09-19 | None | $27 |
| Lilly USA | Meals · 2025-09-10 | Omvoh | $11 |
| Abbvie | Meals · 2025-09-05 | Linzess | $31 |
| Janssen Biotech | Meals · 2025-08-21 | Tremfya | $8 |
| Genzyme | Meals · 2025-08-20 | Dupixent | $123 |
| Abbvie | Meals · 2025-08-14 | Skyrizi | $121 |
| Janssen Biotech | Meals · 2025-08-13 | Tremfya | $22 |
| Abbvie | Meals · 2025-07-31 | Skyrizi | $8 |
| Abbvie | Meals · 2025-07-10 | Linzess | $8 |
| Abbvie | Meals · 2025-07-02 | Linzess | $25 |
| Janssen Biotech | Meals · 2025-07-01 | Tremfya | $20 |
| Phathom Pharmaceuticals | Meals · 2025-06-25 | Voquezna | $149 |
| Janssen Biotech | Meals · 2025-06-17 | Tremfya | $41 |
| Abbvie | Meals · 2025-06-12 | Rinvoq | $18 |
| Janssen Biotech | Education · 2025-06-06 | Tremfya | $79 |
| Abbvie | Meals · 2025-06-05 | Skyrizi | $125 |
| Janssen Biotech | Meals · 2025-06-04 | Tremfya | $16 |
| Abbvie | Meals · 2025-05-30 | Creon | $8 |
| Lilly USA | Meals · 2025-05-28 | Omvoh | $32 |
| Abbvie | Meals · 2025-05-09 | Rinvoq | $28 |
| Abbvie | Meals · 2025-05-03 | Creon | $142 |
| Lilly USA | Meals · 2025-05-01 | Omvoh | $125 |
| Lilly USA | Meals · 2025-04-28 | Omvoh | $35 |
| Abbvie | Meals · 2025-04-24 | Creon | $19 |
| Abbvie | Meals · 2025-04-10 | Rinvoq | $16 |
| Lilly USA | Meals · 2025-04-01 | Omvoh | $35 |
| Abbvie | Meals · 2025-03-31 | Creon | $12 |
| Abbvie | Meals · 2025-03-13 | Creon | $125 |
| Lilly USA | Meals · 2025-03-06 | Omvoh | $14 |
| Janssen Biotech | Meals · 2025-01-29 | Tremfya | $11 |
See earlier years (2024, 2023, 2022)
2024: $14
| Abbvie | Creon | $14 | 1 payment
|
2023: $579
| Abbvie | Linzess | $171 | 5 payments
|
| E.R. Squibb & Sons L.L.C. | Zeposia | $150 | 1 payment
|
| Averitas Pharma | Qutenza | $130 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $128 | 1 payment
|
2022: $233
| Ultragenyx Pharmaceutical | Crysvita | $119 | 1 payment
|
| GlaxoSmithKline | Zejula | $114 | 1 payment
|
Professional record
- NPI
- 1952037400
- Licence
- CA 95022014
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LF0000X (363LF0000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2022-07-27
- NPI last updated
- 2023-02-08
- NPI record certified
- 2023-02-08
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 701 Baltic Cir Unit 739, Redwood City, CA, 94065